Cancer & SURVIVEiT News

FDA expands pembrolizumab indication for first-line treatment of NSCLC On April 11, 2019, the Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck Inc.) for the first-line treatment of patients with…

FDA Approves Lorlatinib for ALK+ NSCLC Jason M. Broderick @jasoncology Published: Friday, Nov 02, 2018 The FDA has granted lorlatinib (Lorbrena) an accelerated approval for the treatment of patients with ALK-positive metastatic non–small…

FDA approves dacomitinib for metastatic non-small cell lung cancer On Sept. 27, 2018, the Food and Drug Administration approved dacomitinib tablets (VIZIMPRO, Pfizer Pharmaceutical Company) for the first-line treatment of…

First-line brigatinib improves PFS for ALK-positive non-small cell lung cancer September 27, 2018 First-line therapy with brigatinib significantly improved PFS compared with crizotinib among treatment-naive patients with advanced ALK-positive non-small cell lung…

World Lung 2018 – Alunbrig squares up to Xalkori, but the field is getting crowded by Jacob Plieth Takeda’s drug leads the charge of small-molecule tyrosine kinase inhibitors, some of…

Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib  Category: Small Molecules Published on Friday, 21 September…

FDA grants nivolumab accelerated approval for third-line treatment of metastatic small cell lung cancer On August 16, 2018, the Food and Drug Administration granted accelerated approval to nivolumab (Opdivo, Bristol-Myers…

FDA grants regular approval for pembrolizumab in combination with chemotherapy for first-line treatment of metastatic nonsquamous NSCLC On August 20, 2018, the Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck…